Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Agile Therapeutics fourth-quarter and full-year 2020 financial results conference call. [Operator instructions] I'd now like to hand the conference over to your speaker today, Matt Riley, head of investor relations and corporate communications. Thank you. Please go ahead.
Matt Riley --
Head of Investor Relations and Corporate Communications
Hello, everyone, and welcome to today's conference call to discuss fourth-quarter and full-year 2020 financial results. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our outlook for the full-year 2021; management's expectations for our future financial and operational performance; our business strategy; our assessment of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgment as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Please refer to our filings with the SEC which are available through the Investor Relations section of our website for information concerning risk factors that may affect the company.